Titan wins FDA nod to study Parkinson’s implant

Titan Pharmaceuticals (NSDQ:TTNP) said today that the FDA cleared the investigational new drug application for its ropinirole implant designed to treat the symptoms of Parkinson’s disease.

The Phase I/II trial, which is slated to enroll 20 patients with idiopathic Parkinson’s disease, will transition patients taking oral ropinirole to Titan’s ropinirole implant for three months of treatment, according to the South San Francisco, Calif.-based company.

Get the full story at our sister site, Drug Delivery Business News.

The post Titan wins FDA nod to study Parkinson’s implant appeared first on MassDevice.

from MassDevice http://ift.tt/2xfoPhp